Download Report

The Chicago Urological Society
In Conjunction with the Chicago Medical Society
RENAL CELL CARCINOMA
KEYNOTE Address: Robert Uzzo, MD, FACS
Fox Chase Cancer Center
12.03.2014
The University Club of Chicago
76 E. Monroe St. Chicago, IL
1:15PM
Target Audience: Urologists
Educa t i on a l Ne e ds
F acu lty List
Renal cell carcinoma is a tumor that is seen frequently
by most urologists. It is estimated that the incidence
of kidney cancer is approximately 60,000 new cases
annually, and the estimated number of deaths may
approach 14,000 cases in 2014 according to the
National Cancer Institute. In the past decade, there
have been numerous technological, surgical and
medical advances that have changed the way in
which we treat kidney cancer based on the size,
location, and presence of metastases. There have
been advances in robotic technology, percutaneous
procedures (such as cryosurgery and radiofrequency
ablation), and even advancements in targeted
therapies. Furthermore, our understanding and
management of small renal masses have led to
greater utilization of surveillance and percutaneous
approaches for select patients. The purpose of this
session is to provide an overview of the latest treatment
strategies of kidney cancer.
Michael R. Abern, MD
Assistant Professor of Urology, Director, Urologic Oncology
University of Illinois at Chicago Department of UrologyChicago, IL
Dr. Abern has disclosed that he does not have any
relevant financial relationships with commercial interests.
Des i red L e ar n i n g Outco me s
At the conclusion of this meeting, the attendee
should be able to:
1. Evaluate a patient with a new diagnosis of renal cell
carcinoma more effectively.
2. Review targeted therapies for renal cell carcinoma
and the indications for their use.
3. Identify a patient with metastatic renal cell
carcinoma and examine the role of cytoreductive
nephrectomy in the era of targeted therapies.
4. Classify the ideal patient who would be a candidate
for minimally invasive/percutaneous treatment
options such as radiofrequency ablation or
cryosurgery.
5. Describe the role of renal biopsy before treatment of
renal cell carcinoma.
6. Discuss the role of surveillance for small renal masses.
Gopal N. Gupta, MD
Assistant Professor, Department of Urology/Surgery, Faculty,
Oncology Institute, Cardinal Bernardin Cancer Center
Loyola University Oncology Research Institute- Maywood, IL
Dr. Gupta has disclosed that he does not have any
relevant financial relationships with commercial interests.
Shilajit Kundu, MD
Chief of Urologic Oncology, Associate Professor in Urology
Northwestern University Feinberg School of Medicine
Chicago, IL
Dr. Kundu has disclosed that he does not have any
relevant financial relationships with commercial interests.
Kent Perry, Jr, MD
Associate Professor in Urology, Co-Director
Division of Minimally Invasive Surgery
Northwestern University Feinberg School of Medicine
Chicago, IL
Dr. Perry has disclosed that he does not have any relevant
financial relationships with commercial interests.
Nicklas Pfanzelter, MD
Assistant Professor of Medicine, Assistant Attending
Physician in Internal Medicine, Div. of HematologyOncology-Cell Therapy Rush University Medical Center
Chicago, IL
Dr. Pfanzelter has disclosed that he does not have any
relevant financial relationships with commercial interests.
Arieh Shalhav, MD
Professor of Surgery, Chief, Section of
Urology, Director, Minimally Invasive Urology
The University of Chicago Medicine-Chicago, IL
Dr. Shalhav has disclosed that he does not have any
relevant financial relationships with commercial interests.
Robert Uzzo, MD, FACS
Chairman, Department of Surgery, Co-Leader,
Genitourinary Cancer Treatment, Attending Surgeon,
Urologic Oncology, G. Willing “Wing” Pepper Chair in
Cancer Research, Professor Fox Chase Cancer Center
Phildelphia, PA
Dr. Uzzo has disclosed that he has been a speaker for Pfizer
and Janssen Biotech.
Mark A. Wille, MD, FACS
Director of Endourology and Stone Disease
Cook County Health and Hospitals System, Division of
Urology-Chicago, IL
Dr. Wille has disclosed that he does not have any relevant
financial relationships with commercial interests.
Progra m i nfo r m at i o n
Wednesday, December 3, 2014
Chairman: Kalyan Latchamsetty, MD
1:15 - 1:35 p.m.
Role of Renal Biopsy for Renal Masses
Mark A. Wille, MD, FACS
1:35 - 2:00 p.m.
Surveillance and Percutaneous Treatments (Cryo/RFA) for Renal Masses
Kent Perry, MD
2:00 - 2:25 p.m.
Update on Targeted Therapies/Immunotherapy for RCC
Nicklas Pfanzelter, MD
2:25 - 2:50 p.m.
Techniques for Robotic Partial Nephrectomy
Gopal Gupta, MD
2:50 - 3:00 p.m.
Comments/Discussion
Robert Uzzo, MD, FACS
3:00 - 3:15 p.m.
Break
3:15 - 3:35 p.m.
Importance of Ischemia Time for Partial Nephrectomy
Arieh Shalhav, MD
3:35 - 4:00 p.m.
Lymph Node Dissection for Renal Cell Carcinoma
Shilajit Kundu, MD
4:00 - 4:30 p.m.
Role of Cytoreductive Nephrectomy in the Era of Targeted Therapies
Michael Abern, MD, BS
4:30 – 4:45 p.m.
Comments/Questions
Robert Uzzo, MD, FACS
4:45 - 5:30 p.m.
Keynote Address
Objectifying Risks in the Management of Localized Kidney Cancer
Robert Uzzo, MD, FACS
5:30 - 7:00 p.m.
Fellowship Mixer
CmE infor m a t i o n
This activity has been planned and implemented in accordance with the accreditation requirements
and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint
providership of the Chicago Medical Society and the Chicago Urological Society. The Chicago Medical
Society is accredited by the ACCME to provide continuing medical education for physicians.
The Chicago Medical Society designates this live activity for a maximum of 4.0 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation
in the activity.
The U n iv e r s i t y C l u b
o f Ch i c a g o
Address:
76 E. Monroe
Chicago, IL 60603
Parking:
Valet parking is available with the doorman
at standard rates of $20 per vehicle.
Self parking is available at the following
garages:
• Grant Park East (Colombus/Michigan)
• Grant Park North (Madison/Michigan)
• Grant Park South (Jackson/Michigan)
• Inter Parking (55 E. Monroe)
Dress Code:
CME P lanning COmm itt ee
The following planning members of
the Chicago Medical Society’s CME
Subcommittee on Joint Providorship have
disclosed that they have no relevant financial
relationships with commercial interests:
Ajay K. Chauhan, MD, Chairman, Howard
Axe, MD, Vickie L. Becker, MD, Adrienne L.
Fregia, MD, Robert W. Panton, MD, Loren
S. Schechter, MD, Kathy M. Tynus, MD and
Cecilia Merino, Director of Education.
The following planning members of the
Chicago Urological Society have disclosed
that they have no relevant financial
relationships with any commercial interests:
Kalyan Latchamsetty, MD, Course Director,
and Jessica Knight, Meeting Coordinator.
Please note The University Club dresscode is
business casual to business attire.
ex h ibi t or s
Actavis
Astellas Pharma US
Auxulium Pharmaceuticals
Bayer
Coloplast
Endo Pharmaceuticals
Ferring
Janssen Biotech, Inc.
Lilly USA
Medivation
Pfizer
Promethus Diagnostics
& Therapeutics
United Therapies
US Army Medical Recruiting
This CME activity did not receive
any educational support.
Registration Information
ONLINE
www.cuschicago.com
Phone
CUS Office: 312-853-2053
Email
info@cuschicago.com